scholarly journals Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019

2019 ◽  
Vol 24 (4) ◽  
Author(s):  
Danuta M Skowronski ◽  
Siobhan Leir ◽  
Suzana Sabaiduc ◽  
Michelle Murti ◽  
James A Dickinson ◽  
...  
Keyword(s):  
Sequence Analysis ◽  
Young Children ◽  
Confidence Interval ◽  
Influenza A ◽  
Age Groups ◽  
Vaccine Effectiveness ◽  
Surveillance Network ◽  
Vaccine Protection ◽  
Influenza A H1n1

Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network assessed interim 2018/19 vaccine effectiveness (VE) against predominant influenza A(H1N1)pdm09 viruses. Adjusted VE was 72% (95% confidence interval: 60 to 81) against medically attended, laboratory-confirmed influenza A(H1N1)pdm09 illness. This substantial vaccine protection was observed in all age groups, notably young children who appeared to be disproportionately affected. Sequence analysis identified heterogeneity in emerging clade 6B.1 viruses but no dominant drift variant.

scholarly journals Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016

2016 ◽  
Vol 21 (11) ◽  
Author(s):  
Catharine Chambers ◽  
Danuta M Skowronski ◽  
Suzana Sabaiduc ◽  
Anne Luise Winter ◽  
James A Dickinson ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Northern Hemisphere ◽  
Influenza A ◽  
Vaccine Effectiveness ◽  
Genetic Evolution ◽  
Significant Protection ◽  
Surveillance Network ◽  
Potential Gain ◽  
Influenza A H1n1

Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2015/16 vaccine effectiveness (VE) against influenza A(H1N1)pdm09 viruses. Adjusted VE showed significant protection of 64% (95% confidence interval (CI): 44–77%) overall and 56% (95%CI: 26–73%) for adults between 20 and 64 years-old against medically attended, laboratory-confirmed A(H1N1)pdm09 illness. Among the 67 A(H1N1)pdm09-positive specimens that were successfully sequenced, 62 (> 90%) belonged to the emerging genetic 6B.1 subclade, defined by S162N (potential gain of glycosylation) and I216T mutations in the haemagglutinin protein. Findings from the Canadian SPSN indicate that the 2015/16 northern hemisphere vaccine provided significant protection against A(H1N1)pdm09 illness despite genetic evolution in circulating viruses.

scholarly journals Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017

2017 ◽  
Vol 22 (6) ◽  
Author(s):  
Danuta M Skowronski ◽  
Catharine Chambers ◽  
Suzana Sabaiduc ◽  
James A Dickinson ◽  
Anne-Luise Winter ◽  
...  
Keyword(s):  
Sequence Analysis ◽  
Confidence Interval ◽  
Influenza Vaccine ◽  
Vaccine Strain ◽  
Influenza A ◽  
Vaccine Effectiveness ◽  
Surveillance Network ◽  
Potential Vaccine ◽  
Substantial Heterogeneity ◽  
Over Time

Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2016/17 influenza vaccine effectiveness (VE) against dominant influenza A(H3N2) viruses considered antigenically matched to the clade 3C.2a vaccine strain. Sequence analysis revealed substantial heterogeneity in emerging 3C.2a1 variants by province and over time. Adjusted VE was 42% (95% confidence interval: 18–59%) overall, with variation by province. Interim virological and VE findings reported here warrant further investigation to inform potential vaccine reformulation.

scholarly journals Influenza Vaccine Effectiveness and Waning Effect in Hospitalized Older Adults. Valencia Region, Spain, 2018/2019 Season

2021 ◽  
Vol 18 (3) ◽  
pp. 1129
Author(s):  
Ainara Mira-Iglesias ◽  
F. Xavier López-Labrador ◽  
Javier García-Rubio ◽  
Beatriz Mengual-Chuliá ◽  
Miguel Tortajada-Girbés ◽  
...  
Keyword(s):  
Older Adults ◽  
Influenza Vaccine ◽  
Influenza A ◽  
Vaccine Effectiveness ◽  
Surveillance Network ◽  
Adjuvanted Vaccine ◽  
Clinical Registries ◽  
Populations At Risk ◽  
Influenza A H1n1 ◽  
Hospitalized Older Adults

Influenza vaccination is annually recommended for specific populations at risk, such as older adults. We estimated the 2018/2019 influenza vaccine effectiveness (IVE) overall, by influenza subtype, type of vaccine, and by time elapsed since vaccination among subjects 65 years old or over in a multicenter prospective study in the Valencia Hospital Surveillance Network for the Study of Influenza and other Respiratory Viruses (VAHNSI, Spain). Information about potential confounders was obtained from clinical registries and/or by interviewing patients and vaccination details were only ascertained by registries. A test-negative design was performed in order to estimate IVE. As a result, IVE was estimated at 46% (95% confidence interval (CI): (16%, 66%)), 41% (95% CI: (−34%, 74%)), and 45% (95% CI: (7%, 67%)) against overall influenza, A(H1N1)pdm09 and A(H3N2), respectively. An intra-seasonal not relevant waning effect was detected. The IVE for the adjuvanted vaccine in ≥75 years old was 45% (2%, 69%) and for the non-adjuvanted vaccine in 65–74 years old was 59% (−16%, 86%). Thus, our data revealed moderate vaccine effectiveness against influenza A(H3N2) and not significant against A(H1N1)pdm09. Significant protection was conferred by the adjuvanted vaccine to patients ≥75 years old. Moreover, an intra-seasonal not relevant waning effect was detected, and a not significant IVE decreasing trend was observed over time.

scholarly journals Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020

2020 ◽  
Vol 25 (7) ◽  
Author(s):  
Danuta M Skowronski ◽  
Macy Zou ◽  
Suzana Sabaiduc ◽  
Michelle Murti ◽  
Romy Olsha ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Influenza Vaccine ◽  
Influenza A ◽  
Vaccine Effectiveness ◽  
Influenza B ◽  
Surveillance Network ◽  
Early Season ◽  
Influenza Illness

Interim results from Canada's Sentinel Practitioner Surveillance Network show that during a season characterised by early co-circulation of influenza A and B viruses, the 2019/20 influenza vaccine has provided substantial protection against medically-attended influenza illness. Adjusted VE overall was 58% (95% confidence interval (CI): 47 to 66): 44% (95% CI: 26 to 58) for A(H1N1)pdm09, 62% (95% CI: 37 to 77) for A(H3N2) and 69% (95% CI: 57 to 77) for influenza B viruses, predominantly B/Victoria lineage.

scholarly journals Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010

2010 ◽  
Vol 15 (18) ◽  
Author(s):  
O Wichmann ◽  
P Stöcker ◽  
G Poggensee ◽  
D Altmann ◽  
D Walter ◽  
...  
Keyword(s):  
Pandemic Influenza ◽  
Influenza A ◽  
Influenza Pandemic ◽  
Rapid Assessment ◽  
Screening Method ◽  
Age Groups ◽  
Vaccine Effectiveness ◽  
Influenza A H1n1 ◽  
Reported Data ◽  
2009 Influenza Pandemic

During the 2009 influenza pandemic, a monovalent AS03-adjuvanted vaccine was almost exclusively used in Germany for immunisation against the 2009 pandemic influenza A(H1N1) virus. One-dose vaccination was recommended for all age groups. We applied the screening method for the rapid assessment of vaccine effectiveness (VE) based on reported data of vaccinated and unvaccinated pandemic influenza cases and vaccination coverage estimates. Preliminary results demonstrate excellent VE in persons aged 14-59 years (96.8%; 95% confidence interval (CI): 95.2-97.9) and moderately high VE in those 60 years or older (83.3%; 95% CI: 71.0-90.5).

scholarly journals Influenza vaccine effectiveness against influenza A in children based on the results of various rapid influenza tests in the 2018/19 season

PLoS ONE ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. e0249005
Author(s):  
Masayoshi Shinjoh ◽  
Norio Sugaya ◽  
Yoshio Yamaguchi ◽  
Ichiro Ookawara ◽  
Yuji Nakata ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Influenza Vaccine ◽  
Diagnostic Tests ◽  
Influenza A ◽  
Control Design ◽  
Case Control ◽  
Vaccine Effectiveness ◽  
Test Results ◽  
Negative Case ◽  
Influenza A H1n1

During influenza epidemics, Japanese clinicians routinely conduct rapid influenza diagnostic tests (RIDTs) in patients with influenza-like illness, and patients with positive test results are treated with anti-influenza drugs within 48 h after the onset of illness. We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children (6 months–15 years old, N = 4243), using a test-negative case-control design based on the results of RIDTs in the 2018/19 season. The VE against influenza A(H1N1)pdm and A(H3N2) was analyzed separately using an RIDT kit specifically for detecting A(H1N1)pdm09. The adjusted VE against combined influenza A (H1N1pdm and H3N2) and against A(H1N1)pdm09 was 39% (95% confidence interval [CI], 30%–46%) and 74% (95% CI, 39%–89%), respectively. By contrast, the VE against non-A(H1N1)pdm09 influenza A (presumed to be H3N2) was very low at 7%. The adjusted VE for preventing hospitalization was 56% (95% CI, 16%–77%) against influenza A. The VE against A(H1N1)pdm09 was consistently high in our studies. By contrast, the VE against A(H3N2) was low not only in adults but also in children in the 2018/19 season.

scholarly journals Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada’s sentinel surveillance network, January 2014

2014 ◽  
Vol 19 (5) ◽  
Author(s):  
D M Skowronski ◽  
C Chambers ◽  
S Sabaiduc ◽  
G De Serres ◽  
J A Dickinson ◽  
...  
Keyword(s):  
Influenza A ◽  
Vaccine Effectiveness ◽  
Sentinel Surveillance ◽  
Surveillance Network ◽  
Binary File ◽  
Influenza A H1n1

Binary file ES_Abstracts_Final_ECDC.txt matches

scholarly journals Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020

2020 ◽  
Vol 25 (10) ◽  
Author(s):  
Angela Rose ◽  
Esther Kissling ◽  
Hanne-Dorthe Emborg ◽  
Amparo Larrauri ◽  
Jim McMenamin ◽  
...  
Keyword(s):  
Primary Care ◽  
Influenza Vaccine ◽  
Influenza A ◽  
Age Groups ◽  
Vaccine Effectiveness ◽  
Influenza B ◽  
European Studies ◽  
Case Definitions ◽  
Point Estimates ◽  
Influenza A H1n1

Background Influenza A(H1N1)pdm09, A(H3N2) and B viruses were co-circulating in Europe between September 2019 and January 2020. Aim To provide interim 2019/20 influenza vaccine effectiveness (VE) estimates from six European studies, covering 10 countries and both primary care and hospital settings. Methods All studies used the test-negative design, although there were some differences in other study characteristics, e.g. patient selection, data sources, case definitions and included age groups. Overall and influenza (sub)type-specific VE was estimated for each study using logistic regression adjusted for potential confounders. Results There were 31,537 patients recruited across the six studies, of which 5,300 (17%) were cases with 5,310 infections. Most of these (4,466; 84%) were influenza A. The VE point estimates for all ages were 29% to 61% against any influenza in the primary care setting and 35% to 60% in hospitalised older adults (aged 65 years and over). The VE point estimates against A(H1N1)pdm09 (all ages, both settings) was 48% to 75%, and against A(H3N2) ranged from −58% to 57% (primary care) and −16% to 60% (hospital). Against influenza B, VE for all ages was 62% to 83% (primary care only). Conclusions Influenza vaccination is of continued benefit during the ongoing 2019/20 influenza season. Robust end-of-season VE estimates and genetic virus characterisation results may help understand the variability in influenza (sub)type-specific results across studies.

scholarly journals Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

2018 ◽  
Vol 23 (9) ◽  
Author(s):  
Marc Rondy ◽  
Esther Kissling ◽  
Hanne-Dorthe Emborg ◽  
Alin Gherasim ◽  
Richard Pebody ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Influenza A ◽  
Age Groups ◽  
Vaccine Effectiveness ◽  
Influenza B ◽  
European Studies ◽  
Influenza A H1n1

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, −42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.

scholarly journals Outbreak of influenza type A (H1N1) in Iporanga, São Paulo State, Brazil

2001 ◽  
Vol 43 (6) ◽  
pp. 311-315 ◽  
Author(s):  
Terezinha Maria de PAIVA ◽  
Maria Akiko ISHIDA ◽  
Kazue Aparecida Yamamoto HANASHIRO ◽  
Regina Maria SCOLARO ◽  
Maria Gisele GONÇALVES ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Influenza A ◽  
Age Groups ◽  
Respiratory Illness ◽  
The Elderly ◽  
Vaccine Protection ◽  
Paulo State ◽  
Influenza A H1n1 ◽  
The Town ◽  
Regional Surveillance

From June to July 1999 an outbreak of acute respiratory illness occurred in the town of Iporanga. Out of a total of 4,837 inhabitants, 324 cases were notified to the Regional Surveillance Service. Influenza virus was isolated from 57.1% of the collected samples and 100% seroconversion to influenza A (H1N1) was obtained in 20 paired sera tested. The isolates were related to the A/Bayern/07/95 strain (H1N1). The percentages of cases notified during the outbreak were 28.4%, 29.0%, 20.7%, 6.2% and 15.7% in the age groups of 0-4, 5-9, 10-14, 15-19 and older than 20 years, respectively. The highest proportion of positives was observed among children younger than 14 years and no cases were notified in people older than 65 years, none of whom had been recently vaccinated against influenza. These findings suggest a significant vaccine protection against A/Bayern/7/95, the H1 component included in the 1997-98 influenza vaccine for elderly people. This viral strain is antigenically and genetically related to A/Beijing/262/95, the H1 component of the 1999 vaccine. Vaccines containing A/Beijing/262/95 (H1N1) stimulated post-immunization hemagglutination inhibition antibodies equivalent in frequency and titre to both A/Beijing/262/95-like and A/Bayern/7/95-like viruses. Thus, this investigation demonstrates the effectiveness of vaccination against influenza virus in the elderly.

Sign in / Sign up

Export Citation Format

Share Document